This meta‐analysis provides substantive evidence supporting the benefits of SGLT‐2 inhibitors in slowing down the deterioration of renal function and the safety of its initial administration, even in patients with renal impairment or without diabetes. The gene discussed is SLC5A2; the disease is diabetes mellitus.